0001209191-21-018327.txt : 20210305
0001209191-21-018327.hdr.sgml : 20210305
20210305175403
ACCESSION NUMBER: 0001209191-21-018327
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210303
FILED AS OF DATE: 20210305
DATE AS OF CHANGE: 20210305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sepp-Lorenzino Laura
CENTRAL INDEX KEY: 0001777421
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 21719856
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS, INC.
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-03
0
0001652130
Intellia Therapeutics, Inc.
NTLA
0001777421
Sepp-Lorenzino Laura
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
0
1
0
0
EVP, Chief Scientific Officer
Stock Option (right to buy)
57.71
2021-03-03
4
A
0
84000
0.00
A
2031-03-02
Common Stock
84000
84000
D
Restricted Stock Unit
2021-03-03
4
A
0
14000
0.00
A
Common Stock
14000
14000
D
This option was granted on March 3, 2021 with respect to 84,000 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
On March 3, 2021, the reporting person was granted 14,000 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments.
/s/Jose Rivera, Attorney-In-Fact
2021-03-05